GeneDx Holdings Corp.

GeneDx Holdings Corp. is a genomics company that provides genetic testing services. Its primary focus is on pediatric and rare disease diagnostics, with an emphasis on whole exome and genome sequencing. The company also offers data and information services, and it has developed an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting. This platform is used for rare disease, hereditary risk, and cancer testing. Founded in 2000 and headquartered in Stamford, Connecticut, GeneDx aims to advance precision medicine through genomic insights.

GeneDx Holdings Corp. is listed on the NasdaqGS exchange under the ticker symbol WGS. The trading currency for its shares is the US Dollar (USD). As a US-based company, it is traded in the United States market, and investors can buy and sell shares on the Nasdaq Global Select Market, which is a major US stock exchange known for listing technology and growth companies.

GeneDx Holdings Corp. operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This means the company is involved in providing diagnostic testing services and research solutions, primarily in the field of genomics. Its work supports healthcare providers in diagnosing rare diseases, assessing hereditary risks, and guiding cancer treatment decisions through advanced genetic analysis.

GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, United States. The company serves the US market primarily, as indicated by its country and region classification. Its genetic testing services, including whole exome and genome sequencing, are offered to healthcare providers and patients across the United States. The company's AI-based platform for genomic analysis also supports clinical reporting for rare disease, hereditary risk, and cancer testing within the US healthcare system.